Warren Buffett Has Held American Express for Decades. Should You Own It Too?

American Express is highlighted as a durable long-term compounder, with 76% of revenue coming from transaction fees and net income rising from $5.2 billion to $10.8 billion over the past decade. The company also cut its share count from 1 billion to 696 million, helping EPS grow from $5.1 to $15.4, or more than 300%. The article is primarily a bullish commentary on business quality and shareholder returns rather than new market-moving information.

Analysis

AXP remains attractive not because it is a pure payments story, but because it monetizes affluent consumer frequency and merchant economics at the same time. The second-order effect is that its earnings are less exposed to revolver stress than the market assumes; in a slower growth environment, the mix can actually improve as premium spend holds up better than discretionary unit volume. That makes AXP a quality compounder, but also caps upside unless transaction growth reaccelerates or buybacks stay unusually aggressive.

The competitive angle is more nuanced than “Amex vs. Visa/Mastercard.” V and MA are infrastructure toll roads with broader acceptance; AXP is a closed-loop brand franchise that wins on spend intensity and loyalty, but it is more exposed to premium travel and dining cycles. If consumer reacceleration broadens, AXP can outperform on leverage to affluent spend; if the cycle turns, its premium positioning becomes a vulnerability because its customer base is less price-sensitive but still cyclical.

The market appears to be underappreciating how much of the per-share story is buyback-driven rather than purely operational. Continued share count reduction can keep EPS growth ahead of revenue for several years, but that support weakens if valuations stay rich and repurchases are forced to slow. The contrarian risk is that investors extrapolate historical compounding without asking whether the next leg requires both benign credit and uninterrupted high-ticket spend.

Near term, the catalyst path is more about guidance and consumer spend cadence than credit quality headline risk. A reacceleration in travel, dining, and business expense could drive multiple expansion over the next 3-6 months, while any deceleration in premium discretionary spend would compress the premium franchise narrative quickly. BRK.B remains a subtle beneficiary only insofar as AXP’s capital return engine supports Berkshire’s financials, but the cleaner trade is relative exposure within payments rather than a broad index bet.

Key Decisions for Investors

• Long AXP vs. short V or MA as a 3-6 month pair: AXP should outperform if affluent discretionary spend and buyback-driven EPS expansion remain intact; stop if acceptance-share narrative reasserts itself or spend growth rolls over.
• Buy AXP on pullbacks tied to temporary consumer-demand weakness, not on strength; target a 12-18 month hold because the equity story is dominated by compounding, not multiple expansion.
• Sell covered calls on AXP against a core long if implied volatility stays elevated: monetizes the market’s tendency to overpay for modest upside in a slow-growth compounder.
• Add BRK.B only as an indirect beneficiary basket hold, not as the primary expression; the cleaner catalyst is still AXP’s capital return engine, not Berkshire beta.
• If premium spend data weakens for 1-2 consecutive quarters, rotate from AXP into MA/V on relative valuation grounds; AXP’s model is more cyclical than the market’s Buffett halo implies.